Related Experiment Videos
Expression, purification, and encephalitogenicity of recombinant human myelin oligodendrocyte glycoprotein
J Bettadapura1, K K Menon, S Moritz
1Neuroimmunology Laboratory, La Trobe University, Bundoora, Victoria, Australia.
Abstract:
Myelin oligodendrocyte glycoprotein (MOG), a putative autoantigen in multiple sclerosis (MS), is a quantitatively minor component of the CNS. In view of the difficulties associated with the purification of MOG from brain tissues, the extracellular domain of human MOG corresponding to the N-terminal 121 amino acids was expressed in Escherichia coli as a glutathione sulfotransferase fusion protein. The expressed protein was localized to inclusion bodies, and varying the growth parameters resulted in the solubilization of small amounts of GST-MOG that could be affinity purified on glutathione agarose columns. The fusion protein found in the inclusion bodies could be solubilized with urea. The solubilized fusion protein was cleaved with thrombin, and the extracellular domain was purified by CM Sephadex 50 chromatography to homogeneity. Injection of recombinant human MOG into different strains of mice resulted in the induction of an MS-like disease, characterized by severe neurological impairment and extensive CNS demyelinated lesions. Recombinant MOG produced in E. coli should prove to be useful as a highly purified biological reagent for immunological, pathological, functional, and structural studies.
Insights
Researchers produced recombinant human myelin oligodendrocyte glycoprotein (MOG) in E. coli. This purified MOG induced a multiple sclerosis (MS)-like disease in mice, offering a valuable tool for MS research.
Area of Science:
- Neuroimmunology
- Protein biochemistry
Background:
- Myelin oligodendrocyte glycoprotein (MOG) is implicated in multiple sclerosis (MS).
- Purification of native MOG from CNS tissue is challenging.
Purpose of the Study:
- To develop a method for producing purified recombinant human MOG.
- To investigate the potential of recombinant MOG to induce an MS-like disease in vivo.
Main Methods:
- Expression of the extracellular domain of human MOG as a GST-fusion protein in E. coli.
- Solubilization, cleavage, and purification of recombinant MOG using affinity chromatography and ion-exchange chromatography.
- Induction of experimental autoimmune encephalomyelitis (EAE) in mice using purified recombinant MOG.
Main Results:
- Recombinant human MOG was successfully purified to homogeneity.
- Injection of recombinant MOG induced a severe MS-like disease in mice, characterized by neurological deficits and demyelination.
- The induced disease exhibited pathological features consistent with human MS.
Conclusions:
- Recombinant MOG produced in E. coli is a viable and highly purified reagent.
- This recombinant MOG can effectively induce an MS-like autoimmune disease in animal models.
- The findings support the use of recombinant MOG for further immunological and pathological studies of MS.